PubMed=11261825; DOI=10.1023/A:1006461422273
Santner S.J., Dawson P.J., Tait L., Soule H.D., Eliason J., Mohamed A.N., Wolman S.R., Heppner G.H., Miller F.R.
Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells.
Breast Cancer Res. Treat. 65:101-110(2001)

PubMed=14523048; DOI=10.1172/JCI18899
Tang B., Vu M., Booker T., Santner S.J., Miller F.R., Anver M.R., Wakefield L.M.
TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression.
J. Clin. Invest. 112:1116-1124(2003)

PubMed=20169162; DOI=10.1371/journal.pone.0009201
Kadota M., Yang H.H., Gomez B., Sato M., Clifford R.J., Meerzaman D., Dunn B.K., Wakefield L.M., Lee M.P.
Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines.
PLoS ONE 5:E9201-E9201(2010)

PubMed=20543960; DOI=10.1371/journal.pone.0011030
Choong L.-Y., Lim S., Chong P.-K., Wong C.-Y., Shah N., Lim Y.-P.
Proteome-wide profiling of the MCF10AT breast cancer progression model.
PLoS ONE 5:E11030-E11030(2010)